Adtran accelerates broadband rollouts with market’s most scalable fiber access platform
24.1.2023 18:12:00 EET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, today launched its SDX 6330 10Gbit/s Combo PON fiber access platform, enabling service providers to rapidly and cost-effectively connect homes and businesses with fiber-based broadband. The new open and disaggregated solution offers the industry’s highest port density and is the first optical line terminal (OLT) with integrated 400Gbit/s uplinks. It will empower operators to accelerate fiber rollout and easily scale their networks to support dense urban, suburban and rural deployments. With enhanced energy efficiency, the highly compact, temperature-hardened fiber access platform will be important to meeting sustainability targets and addressing market demands for both retail and wholesale providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230124005747/en/
Adtran’s SDX 6330 will help service providers meet subscriber demand in the most scalable and sustainable way possible. (Photo: Business Wire)
“Service providers face a tough environment as they strive to keep up with growing subscriber needs, expand coverage and meet green targets. With households and businesses accessing more and more data-hungry applications, operators need strategies in place to handle the surge in a cost-effective and sustainable way. This challenge is precisely what our third-generation fiber access platform aims to address,” said Robert Conger, SVP of technology and strategy at Adtran. “Our SDX 6330 offers the network simplicity, sustainability and scalability needed to power the Gigabit Society. That’s what makes it a compelling alternative to chassis-based architectures. It’s the solution many operators are searching for as they look to expand their market share while improving customer experience.”
The SDX 6330 is Adtran’s third generation of open and disaggregated OLT devices. With 48 ports of Combo PON in a compact and power-efficient design, it sets a new benchmark for lowering the total cost of deployment for 10Gbit/s services. Designed to deliver network simplicity and sustainability at scale, the solution offers deployment versatility and improved reach. Featuring open interfaces, it provides freedom to build best-in-class infrastructure with technology from multiple vendors, and its versatile architecture supports a wide range of network topologies and coherent optics. The SDX 6330 also helps meet corporate sustainability objectives by reducing power demand and landfill requirements.
“Our SDX 6330 is the most advanced fiber access platform in the industry, and the impact it’s about to have will be significant. By empowering service providers to reduce both the time and cost of getting people connected, we’re going to see broadband coverage increase like never before,” commented Ronan Kelly, CTO for EMEA and APAC at Adtran. “As pioneers in open and disaggregated fiber access innovation, we’ve consistently pushed boundaries, beginning with our industry-first deployments dating back to 2017. Now with our third-generation device, we’re taking density and scalability to new heights. Our SDX 6330 will transform networks into flexible, multigigabit service delivery platforms, empowering operators to stay ahead of the bandwidth consumption curve.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005747/en/
Contact information
For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors
Rhonda Lambert
t +1 256-963-7450
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom